Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Muscle Protein Synthesis
- Sponsor
- University of Nottingham
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Muscle protein synthesis in response to leucine feeding
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
Sarcopenia describes the progressive decline of muscle mass and strength with advancing age and is associated with increased frailty and morbidity, however we do not currently have an effective treatment. Protein feeding and exercise is known to increase muscle mass, but aged muscle shows a lower response to these stimuli leading to muscle loss over time. We do know that ingesting leucine, a building block of protein, can overcome this reduced response to protein feeding and exercise leading to increased muscle mass in older people. However, we do not understand when the optimum time to ingest leucine is to maximise muscle mass after exercise in older people. In this study we will examine the effect of feeding leucine after exercise either with a meal or between meals.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male, 65-75 years of age
- •BMI 18-28 kg/m2
- •Non smoker
- •Not performing regular resistance type exercise
- •Participant is willing and able to give informed consent for participation in the study
Exclusion Criteria
- •A BMI \<18 or \>28 kg·m-2
- •Active cardiovascular disease: uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event
- •Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
- •Respiratory disease including pulmonary hypertension or chronic obstructive pulmonary disease (COPD)
- •Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn/ congenital errors of metabolism (e.g. phenylketonuria (PKU), galactosaemia)
- •Active inflammatory bowel disease
- •Acute infection
- •Acute or chronic renal disease
- •Malignancy (or history of malignancy with 5 y)
- •Recent steroid treatment (within 6 mo), or hormone replacement therapy
Outcomes
Primary Outcomes
Muscle protein synthesis in response to leucine feeding
Time Frame: 7 days
To quantify muscle protein synthesis in response to feeding leucine with a meal or in-between meals using mass spectrometry.
Secondary Outcomes
- Measure muscle anabolic and catabolic signalling pathways in response to leucine feeding(7 days)